Definitive Healthcare (NASDAQ:DH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Definitive Healthcare (NASDAQ:DH) from a hold rating to a buy rating in a report published on Sunday morning,Wall Street Zen reports.

A number of other research firms also recently issued reports on DH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Monday, August 31st. Morgan Stanley reduced their price target on shares of Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a report on Tuesday, August 11th. Bank of America reaffirmed an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. BTIG Research reaffirmed a “neutral” rating on shares of Definitive Healthcare in a research report on Friday, September 4th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $1.00 price objective on shares of Definitive Healthcare in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $1.47.

Definitive Healthcare Stock Down 2.0%

Shares of NASDAQ:DH opened at $1.00 on Friday. The company has a market capitalization of $106.75 million, a price-to-earnings ratio of -0.62, a P/E/G ratio of 12.59 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86. The business’s 50-day moving average is $0.80 and its 200-day moving average is $0.91. Definitive Healthcare has a 1 year low of $0.61 and a 1 year high of $4.35.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Monday, August 10th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The business had revenue of $55.20 million during the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Equities research analysts predict that Definitive Healthcare will post 0.06 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC boosted its holdings in shares of Definitive Healthcare by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock worth $292,000 after buying an additional 111,634 shares during the last quarter. Corient Private Wealth LP bought a new stake in Definitive Healthcare during the 2nd quarter valued at $378,000. Williams & Novak LLC raised its stake in shares of Definitive Healthcare by 155.8% during the 2nd quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock valued at $65,000 after purchasing an additional 47,880 shares during the period. Irenic Capital Management LP purchased a new stake in shares of Definitive Healthcare in the first quarter worth about $71,000. Finally, Flywheel Private Wealth LLC purchased a new stake in Definitive Healthcare in the 1st quarter worth approximately $83,000. 98.67% of the stock is currently owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.